Asymptomatic reactivation of JC virus in patients treated with natalizumab.
Warnke
Clemens
C
Adams
Ortwin
O
Kieseier
Bernd C
BC
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D004279:DNA, Viral / Q000097:blood; D006801:Humans; D039441:Integrin alpha4 / Q000276:immunology; D007577:JC Virus / Q000235:genetics / Q000302:isolation & purification* / Q000502:physiology; D007963:Leukocytes, Mononuclear / Q000821:virology; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab; D019562:Viral Load; D014766:Viremia; D014775:Virus Activation / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004279:DNA, Viral; D000069442:Natalizumab; D039441:Integrin alpha4